Abstract
At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Consortia
Additional information
'Nolvadex' is a property of Imperial Chemical Industries plc.
Members of the Steering Committee were: M. Baum (Chairman), D.M. Brinkley, J.A. Dosset, K. McPherson, I.M. Jackson, R.D. Rubens, F.G. Smiddy, B.A. Stoll, A.J. Wilson, I.H. Birch & M.K. Palmer.
Rights and permissions
About this article
Cite this article
Analysis at Eight Years by 'Nolvadex'., Adjuvant Trial Organisation.. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57, 608–611 (1988). https://doi.org/10.1038/bjc.1988.138
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.138
- Springer Nature Limited
This article is cited by
-
The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer
Current Atherosclerosis Reports (2023)
-
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Nature Reviews Clinical Oncology (2022)
-
Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform
BMC Cancer (2021)
-
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
Current Treatment Options in Oncology (2018)
-
Status of adjuvant endocrine therapy for breast cancer
Breast Cancer Research (2014)